ArticleClinical and translational gastroenterology2017
The Role of Gut-brain Axis in Regulating Glucose Metabolism After Acute Pancreatitis.
Article in Clinical and translational gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Risk factors for diabetes mellitus after acute pancreatitis: a systematic review and meta-analysis.Frontiers in medicine · 2023Pooled it
- The Roles of Gut Microbiota in the Pathogenesis of Acute Pancreatitis.Medical science monitor : international medical journal of experimental and clinical research · 2026Review
- Gut Peptide Alterations in Type 2 Diabetes and Obesity: A Narrative Review.Current obesity reports · 2026Review
- A radiomics model of contrast-enhanced computed tomography for predicting post-acute pancreatitis diabetes mellitus.Quantitative imaging in medicine and surgery · 2024Article
- Article
- Machine learning for post-acute pancreatitis diabetes mellitus prediction and personalized treatment recommendations.Scientific reports · 2023Article
- Pancreatic and gut hormones as predictors of new-onset prediabetes after non-necrotising acute pancreatitis: a prospective longitudinal cohort study.Endocrine connections · 2021Article
- Probiotics Alleviate the Progressive Deterioration of Motor Functions in a Mouse Model of Parkinson's Disease.Brain sciences · 2020Article
- Oxyntomodulin May Distinguish New-Onset Diabetes After Acute Pancreatitis From Type 2 Diabetes.Clinical and translational gastroenterology · 2020Observational
- Metabolic Trifecta After Pancreatitis: Exocrine Pancreatic Dysfunction, Altered Gut Microbiota, and New-Onset Diabetes.Clinical and translational gastroenterology · 2019Article
- Antidiabetic Medications and Mortality Risk in Individuals With Pancreatic Cancer-Related Diabetes and Postpancreatitis Diabetes: A Nationwide Cohort Study.Diabetes care · 2019Article
- Global epidemiology and holistic prevention of pancreatitis.Nature reviews. Gastroenterology & hepatology · 2019Review
- Profile of Gut Hormones, Pancreatic Hormones and Pro-inflammatory Cytokines in New Zealand Maori.Gastroenterology research · 2018Article
- Pro-inflammatory cytokines after an episode of acute pancreatitis: associations with fasting gut hormone profile.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2018Article
- Calcitonin gene-related peptide: neuroendocrine communication between the pancreas, gut, and brain in regulation of blood glucose.Annals of translational medicine · 2017Article
- Associations between circulating levels of adipocytokines and abdominal adiposity in patients after acute pancreatitis.Clinical and experimental medicine · 2017Article
- Gastrin-Releasing Peptide and Glucose Metabolism Following Pancreatitis.Gastroenterology research · 2017Article
- Insights on glicentin, a promising peptide of the proglucagon family.Biochemia medica · 2017Review
- Glucose Variability Measures as Predictors of Oral Feeding Intolerance in Acute Pancreatitis: A Prospective Pilot Study.Digestive diseases and sciences · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesDiabetes has become an epidemic in developed and developing countries alike, with an increased demand for new efficacious treatments. A large body of pre-clinical evidence suggests that the gut-brain axis may be exploited as a potential therapeutic target for defective glucose homeostasis. This clinical study aimed to investigate a comprehensive panel of glucoregulatory peptides, released by both the gut and brain, in individuals after acute pancreatitis.
methodsFasting levels of glucagon-like peptide-1 (GLP-1), glicentin, oxyntomodulin, peptide YY, ghrelin, cholecystokinin, vasoactive intestinal peptide (VIP), and secretin were studied. Modified Poisson and multivariable linear regression analyses were conducted. Pre-determined concentration ranges were used to categorize each peptide into quartiles.
resultsA total of 83 individuals were included, of who 30 (36%) developed abnormal glucose metabolism (AGM) after acute pancreatitis. In individuals with AGM, the highest quartile of oxyntomodulin differed most significantly from the lowest quartile with a prevalence ratio (PR; 95% confidence interval) of 0.50 (0.21, 1.20; P=0.005); of glicentin with a PR of 0.26 (0.13, 0.54; P<0.001); and of VIP with a PR of 0.34 (0.13, 0.89; P=0.043). Peptide YY, GLP-1, cholecystokinin, ghrelin, and secretin were not significantly associated with AGM.
conclusionsFasting circulating oxyntomodulin, glicentin, and VIP levels are significantly decreased in patients with defective glucose homeostasis after acute pancreatitis. Oxyntomodulin appears to be a promising therapeutic target for future clinical studies on diabetes associated with diseases of the exocrine pancreas.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.